Nxera Pharma has acquired rights to NBI-’567 through Neurocrine Biosciences, with the goal of improving patient outcomes in Japan.
2 reports, 1 independent
Updated Aug 26
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nxera Pharma has acquired rights to NBI-’567 through Neurocrine Biosciences, with the goal of improving patient outcomes in Japan.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nxera Pharma
company in Tokyo, Japan
Nothing else this week.
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.